ALZN - CIK 0001677077
The table below shows Alzamend Neuro, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q3 2025 | Q2 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $1.28M | $176.28K | $1.74M | $447.11K | $311.09K | $206.57K |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $919.02K |
| $821.83K |
| $959.33K |
| $590.30K |
| $1.05M |
| $755.83K |
| Operating income | -$2.20M | -$998.11K | -$2.70M | -$1.04M | -$1.36M | -$962.40K |
| Income tax | - | - | - | - | - | - |
| Net income | -$2.20M | -$1.00M | -$2.70M | -$1.04M | -$1.36M | -$974.41K |
| EPS (diluted) | -$0.58 | -$0.30 | -$1.28 | -$1.75 | -$3.61 | -$11.42 |